Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
49
TARA Quote, Financials, Valuation and Earnings
Last price:
$5.48
Seasonality move
:
27.06%
Day range:
$5.46 - $5.80
52-week range:
$2.77 - $7.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.66x
Volume:
700.5K
Avg. volume:
1M
1-year change:
-8.03%
Market cap:
$219.9M
Revenue:
--
EPS (TTM):
-$1.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TARA
Protara Therapeutics, Inc.
|
-- | -$0.39 | -- | -27.03% | $25.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TKNO
Alpha Teknova, Inc.
|
$10.2M | -- | 4.54% | -25.37% | $10.00 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TARA
Protara Therapeutics, Inc.
|
$5.70 | $25.00 | $219.9M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.71 | $0.85 | $341.5M | 4.55x | $0.80 | 0% | 5.27x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $688.4K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TKNO
Alpha Teknova, Inc.
|
$4.71 | $10.00 | $252.1M | -- | $0.00 | 0% | 6.32x |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.3M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TARA
Protara Therapeutics, Inc.
|
2.69% | -2.221 | 2.18% | 13.49x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TKNO
Alpha Teknova, Inc.
|
28.52% | 0.640 | 8.75% | 3.94x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TARA
Protara Therapeutics, Inc.
|
-$88K | -$14.8M | -37.51% | -38.66% | -- | -$12.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TKNO
Alpha Teknova, Inc.
|
$2.9M | -$4M | -16.72% | -22.95% | -38.43% | -$2.4M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Protara Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TARA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Protara Therapeutics, Inc.'s net margin of -255.85%. Protara Therapeutics, Inc.'s return on equity of -38.66% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TARAProtara Therapeutics, Inc.-- -$0.31 $135.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TARA or NBY?
Protara Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 338.6%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -68.64%. Given that Protara Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Protara Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TARAProtara Therapeutics, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TARA or NBY More Risky?
Protara Therapeutics, Inc. has a beta of 1.385, which suggesting that the stock is 38.466% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TARA or NBY?
Protara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Protara Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TARA or NBY?
Protara Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Protara Therapeutics, Inc.'s net income of -$13.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Protara Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics, Inc. is -- versus 5.27x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TARAProtara Therapeutics, Inc.-- -- -- -$13.3M NBYNovaBay Pharmaceuticals, Inc.5.27x 4.55x $521K -$1.3M
-
Which has Higher Returns TARA or OGEN?
Oragenics, Inc. has a net margin of -- compared to Protara Therapeutics, Inc.'s net margin of --. Protara Therapeutics, Inc.'s return on equity of -38.66% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital TARAProtara Therapeutics, Inc.-- -$0.31 $135.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About TARA or OGEN?
Protara Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 338.6%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.09%. Given that Protara Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Protara Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TARAProtara Therapeutics, Inc.6 0 0 OGENOragenics, Inc.1 0 0 -
Is TARA or OGEN More Risky?
Protara Therapeutics, Inc. has a beta of 1.385, which suggesting that the stock is 38.466% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock TARA or OGEN?
Protara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TARA or OGEN?
Protara Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Protara Therapeutics, Inc.'s net income of -$13.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Protara Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TARAProtara Therapeutics, Inc.-- -- -- -$13.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns TARA or PTN?
Palatin Technologies has a net margin of -- compared to Protara Therapeutics, Inc.'s net margin of --. Protara Therapeutics, Inc.'s return on equity of -38.66% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TARAProtara Therapeutics, Inc.-- -$0.31 $135.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About TARA or PTN?
Protara Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 338.6%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Protara Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Protara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TARAProtara Therapeutics, Inc.6 0 0 PTNPalatin Technologies0 0 0 -
Is TARA or PTN More Risky?
Protara Therapeutics, Inc. has a beta of 1.385, which suggesting that the stock is 38.466% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TARA or PTN?
Protara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TARA or PTN?
Protara Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Protara Therapeutics, Inc.'s net income of -$13.3M is higher than Palatin Technologies's net income of --. Notably, Protara Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TARAProtara Therapeutics, Inc.-- -- -- -$13.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns TARA or TKNO?
Alpha Teknova, Inc. has a net margin of -- compared to Protara Therapeutics, Inc.'s net margin of -41%. Protara Therapeutics, Inc.'s return on equity of -38.66% beat Alpha Teknova, Inc.'s return on equity of -22.95%.
Company Gross Margin Earnings Per Share Invested Capital TARAProtara Therapeutics, Inc.-- -$0.31 $135.9M TKNOAlpha Teknova, Inc.27.92% -$0.08 $101.6M -
What do Analysts Say About TARA or TKNO?
Protara Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 338.6%. On the other hand Alpha Teknova, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 91.08%. Given that Protara Therapeutics, Inc. has higher upside potential than Alpha Teknova, Inc., analysts believe Protara Therapeutics, Inc. is more attractive than Alpha Teknova, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TARAProtara Therapeutics, Inc.6 0 0 TKNOAlpha Teknova, Inc.4 2 0 -
Is TARA or TKNO More Risky?
Protara Therapeutics, Inc. has a beta of 1.385, which suggesting that the stock is 38.466% more volatile than S&P 500. In comparison Alpha Teknova, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TARA or TKNO?
Protara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics, Inc. pays -- of its earnings as a dividend. Alpha Teknova, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TARA or TKNO?
Protara Therapeutics, Inc. quarterly revenues are --, which are smaller than Alpha Teknova, Inc. quarterly revenues of $10.5M. Protara Therapeutics, Inc.'s net income of -$13.3M is lower than Alpha Teknova, Inc.'s net income of -$4.3M. Notably, Protara Therapeutics, Inc.'s price-to-earnings ratio is -- while Alpha Teknova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics, Inc. is -- versus 6.32x for Alpha Teknova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TARAProtara Therapeutics, Inc.-- -- -- -$13.3M TKNOAlpha Teknova, Inc.6.32x -- $10.5M -$4.3M
-
Which has Higher Returns TARA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Protara Therapeutics, Inc.'s net margin of --. Protara Therapeutics, Inc.'s return on equity of -38.66% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TARAProtara Therapeutics, Inc.-- -$0.31 $135.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About TARA or TOVX?
Protara Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 338.6%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3121.35%. Given that Theriva Biologics, Inc. has higher upside potential than Protara Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Protara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TARAProtara Therapeutics, Inc.6 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is TARA or TOVX More Risky?
Protara Therapeutics, Inc. has a beta of 1.385, which suggesting that the stock is 38.466% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock TARA or TOVX?
Protara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TARA or TOVX?
Protara Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Protara Therapeutics, Inc.'s net income of -$13.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Protara Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TARAProtara Therapeutics, Inc.-- -- -- -$13.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
37
OKLO alert for Dec 16
Oklo, Inc. [OKLO] is down 5.81% over the past day.
Sell
43
SEI alert for Dec 16
Solaris Energy Infrastructure, Inc. [SEI] is down 5.3% over the past day.
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 21.85% over the past day.
